![]() |
|
|
Vol. 295, Issue 3, 1241-1248, December 2000
Neuronal Excitability Section, Epilepsy Research Branch, National
Institute of Neurological Disorders and Stroke, National Institutes of
Health, Bethesda, Maryland
Ganaxolone (3
-hydroxy-3
-methyl-5
-pregnane-20-one), an orally
active synthetic analog of the neuroactive steroid allopregnanolone, is
a positive allosteric modulator of
-aminobutyric
acidA receptors with anticonvulsant properties. We
sought to determine whether tolerance occurs to the anticonvulsant
activity of ganaxolone in the pentylenetetrazol seizure test and
whether there is cross-tolerance with diazepam. Rats were treated with
two daily injections of a 2 × ED50 dose of ganaxolone
(7 mg/kg s.c.), diazepam (4 mg/kg i.p.), or vehicle for 3 or 7 days. On
the day after the chronic treatment periods, the anticonvulsant
potencies of ganaxolone and diazepam were determined. The
ED50 values for ganaxolone after 3- and 7-day treatment
with ganaxolone were not significantly different from that in naive
rats (ED50 = 3.5 mg/kg). In contrast, in animals that
were treated chronically with ganaxolone for 7 days, there was a
significant reduction in the anticonvulsant potency of diazepam
(ED50 = 4.0 versus 1.9 mg/kg for naive controls). Chronic treatment with diazepam was not associated with a reduction in
the potency of ganaxolone, but there was a reduction in the potency of
diazepam (ED50 = 3.7 mg/kg). Plasma ganaxolone
determinations indicated that the pharmacokinetic properties of
ganaxolone were unchanged after 7-day chronic ganaxolone treatment. The
estimated equilibrium plasma concentrations of ganaxolone associated
with threshold (750-950 ng/ml) and 50% seizure protection (1215-1295 ng/ml) were similar in naive and chronically treated rats. We conclude
that there is no tolerance to the anticonvulsant activity of ganaxolone
nor is there cross-tolerance to ganaxolone when tolerance develops to
diazepam. However, there is cross-tolerance to diazepam with chronic
ganaxolone treatment.
This article has been cited by other articles:
![]() |
D. Zhu, V. Birzniece, T. Backstrom, and G. Wahlstrom Dynamic aspects of acute tolerance to allopregnanolone evaluated using anaesthesia threshold in male rats Br. J. Anaesth., October 1, 2004; 93(4): 560 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Mascia, F. Biggio, L. Mancuso, S. Cabras, P. L. Cocco, G. Gorini, A. Manca, C. Marra, R. H. Purdy, P. Follesa, et al. Changes in GABAA Receptor Gene Expression Induced by Withdrawal of, but Not by Long-Term Exposure to, Ganaxolone in Cultured Rat Cerebellar Granule Cells J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1014 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. McMahon and C. P. France Daily Treatment with Diazepam Differentially Modifies Sensitivity to the Effects of gamma -Aminobutyric AcidA Modulators on Schedule-Controlled Responding in Rhesus Monkeys J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1017 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. McMahon, L. R. Gerak, and C. P. France Potency of Positive gamma -Aminobutyric AcidA Modulators to Substitute for a Midazolam Discriminative Stimulus in Untreated Monkeys Does Not Predict Potency to Attenuate a Flumazenil Discriminative Stimulus in Diazepam-Treated Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1227 - 1235. [Abstract] [Full Text] [PDF] |
||||